Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Summary

This study is a single arm, multi-center, prospective clinical trial. The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung cancer, who have progressed on or less than 6 month after platinum-based first-line therapy.

Timeline

Start

2024-04-17

Primary completion

2026-04-30

Completion

2026-12-31

Drugs

Indications